ArticleLife (Basel, Switzerland)2026
Analysis of Prognostic Significance of CD47 Expression in Newly Diagnosed Large B Cell Lymphoma.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD47 is a transmembrane protein that possesses the ability to inhibit macrophage phagocytosis, enabling immune system evasion. While CD47 overexpression is associated with a poor prognosis in solid malignancies, data on its prognostic significance in lymphomas are inconsistent. This study aimed to evaluate the clinical and prognostic significance of CD47 expression in patients with large B-cell lymphoma (LBCL). In this study biopsy specimens from 146 patients diagnosed with LBCL and treated with immunochemotherapy were analyzed. CD47 expression was assessed using standard immunohistochemical methods. A high level of CD47 expression was detected in 30 (20.5%) patients. High CD47 expression was more frequently observed in patients with high β2-microglobulin levels and extranodal disease compared to nodal LBCL. No significant difference in CD47 expression was observed between gastrointestinal LBCL and other extranodal localizations. CD47 positivity had no significant influence on progression-free survival (PFS) and overall survival (OS); however, a trend toward shorter PFS and OS was noted (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.